@nicoladalbeth.bsky.social
Rheumatologist, Tāmaki Makaurau
Thanks for your G-CAN posting, so great for those of us not able to make the meeting in person!
24.10.2025 07:04 — 👍 1 🔁 0 💬 1 📌 0🌟Meet Dr. Francisca Sivera, the new EULAR Education Committee Chair!
She assumes this role with a strong commitment to collaborating with diverse professionals to advance high-quality rheumatology training across Europe.
Watch the full interview here: https://pulse.ly/p3iftscuzf
A collaborative journey in crystal arthritis Tony Merriman UAB University of Otago
The #GCAN2025 Gold Medal Award goes to Tony Merriman of UAB for his work, his mentorship, and his service
My favorite are these talks where we hear about someone's career but also their reflections on what has mattered
#ACR25
Tony Merriman gives shoutout to @nicoladalbeth.bsky.social "who proudly told me last week that she would sleep through my talk" 😆
I mean, it's like 2am in NZ right now
#GCAN2025
Great start to #GCAN2025 with strong representation from STOP-Gout trial, fun great debate (with hats), proud of mentee presentations, & great to see collaborators in person with #Burt
@rheumcat.bsky.social @nicoladalbeth.bsky.social
bar graph showing that RCTs have more male populations and don't capture the very young or very old
Outcomes
#GCAN2025 year in review
Liu et al
RCTs and registries for gout are not representative of the US population and tx effects may not be generalizable
#ACR25
29 ECI abstracts submitted Expanded program attendance - hybrid in person and virtual
Chair Dr Bob Terkeltaub shows the growth of this meeting @g-cangout.bsky.social #GCAN2025
Thanks for continuing to have this meeting as hybrid, even if the meeting is right before #ACR25
Taking a week + out for travel is often not possible
Prof Dalbeth wearing a blue cap with the number 6 on it
idk, that felt like a really effective debate strategy from @nicoladalbeth.bsky.social 🧢
#GCAN2025 #ACR25
61% vote against the resolution
Dalbeth rebuttal:
-data presented do not represent the average pt with gout
Final vote: 61% vote no
#GCAN2025 #ACR25
⭐CPPD nomenclature - Silvia Sirotti and Georgios Filippou
We are deep in the Delphi rounds right now and I must confess I no longer remember what each P and each D stands for at this point 😵💫
(And I thought axSpA nomenclature discussions were wild)
#GCAN2025 #ACR25
Dr. Tim Kwok emphasized that “difficult-to-treat gout” goes beyond urate levels, involving persistent inflammation, reduced function, and higher healthcare use. A holistic approach addressing clinical, patient, and system factors is key. #2025GCAN #Gout #Rheumatology
22.10.2025 21:47 — 👍 5 🔁 2 💬 0 📌 0
70% voting for the statement
#GCAN2025 Great Debate: : The Standard Serum Urate Target in Gout Should Be < 5mg/dL for the Average Patient
Pro: Thomas Bardin
Con: @nicoladalbeth.bsky.social
Audience pre-vote in support of the statement
#ACR25
Forest plot of independent factors selected in the reduced multiple logistic regression explaining definitive flare resolution by day 3 defined by a change in pain visual analogic scale (VAS) from baseline of 50% or more and/or pain VAS <40/100 by day 3 (48 hours) and no further use of anti-inflammatory agents. Odds ratios (ORs) and their 95% confidence interval of variables selected in the reduced model are presented.
Post hoc analysis of the COLCHICORT trial (colchicine vs prednisone for acute CPP crystal arthritis) identified factors predictive of arthritis resolution. Prednisone appeared to perform better in achieving pain relief after 2 days of treatment
AC&R
doi.org/10.1002/acr....
#Medsky
Spermidine reproduces the anti-inflammatory effects of intermittent fasting and prevents urate and calcium pyrophosphate crystal-induced inflammation. Graphical abstract created with BioRender
Mouse model study found short-term intermittent fasting prevented crystal-induced inflammation & induced production of anti-inflammatory metabolites, such as ketone body BHB, corticosterone, & spermidine. Spermidine supplementation reproduced anti-inflammatory effects
A&R
doi.org/10.1002/art....
Distribution of agreeable to take a medication to reduce serum urate scores (0=not at all agreeable, 10= extremely agreeable)
International survey study of people with asymptomatic hyperuricemia looked at perceptions about hyperuricemia and urate-lowering therapy. Hyperuricemia was not well understood, and most perceived minimal consequences of asymptomatic hyperuricemia
AC&R
doi.org/10.1002/acr....
#Medsky
Thanks to @medscape.com for highlighting our work
www.medscape.com/viewarticle/...
Risk of Primary and Secondary Outcomes with NSAIDs versus Colchicine, Propensity Score-Matching (Top) and Inverse Probability of Treatment Weighting (Bottom)
Target trial emulations compared CV safety of NSAIDs vs colchicine among patients with gout starting allopurinol, and found NSAID prophylaxis was associated with higher risk of CV events than colchicine or no prophylaxis
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky #Rheumsky
✨July Issue✨| Factors beyond urate levels for managing gout flares
In this Comment article, the authors highlight the importance of considering factors beyond urate levels to prevent gout flares and improve the quality of life of individuals with gout.
bit.ly/4liJVTL
#Rheumsky #Medsky
Addressing patients’ expectations can enhance treatment outcomes and reduce adverse effects.
This JAMA Insights offers four communication strategies to improve clinician-patient interactions.
ja.ma/3Hsek2L #MedSky #MedEd
Responder rate (serum urate ≤6.0 mg/dL) over time (full analysis set). LOCF, last observation carried forward
Phase 3 RCT in Chinese patients with gout showed dotinurad 4 mg/day was superior to febuxostat 40 mg/day in achieving serum urate levels ≤6.0 mg/dL at week 24. Treatment-emergent AE incidence was similar between treatment groups
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
Feels like a good time to share this - Don McGlashan playing Anchor Me last week for RNZ, a stunning version
youtu.be/qlAJjSpi5T0?...
June Arthritis Care & Research Editor's Pick banner
Arthritis Care & Research June Editor's Pick
👉 Gout Flares After Stopping Anti-Inflammatory Prophylaxis: A Rapid Literature Review and Meta-Analysis
doi.org/10.1002/acr....
✨June Issue✨| Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition
Jauffret & Pascart highlight some of the hurdles in advancing the understanding of the epidemiology of calcium pyrophosphate crystal deposition
bit.ly/4kDBPnB
#Rheumsky #Medsky
Serum urate has been used as a surrogate marker for gout flares in gout clinical trial design. Commentary in A&R discusses the importance of gout flare and calls for greater focus on gout flare as a clinical trial outcome
doi.org/10.1002/art....
#Medsky #Rheumsky
Gout and NLRP3 inflammasome biology. Graphical abstract created with BioRender
New installment in the A&R immunology series describes 3 broad stages of acute inflammation in gout: initiation, leukocyte mobilization, & self-resolution, and examines the role of the NLRP3 inflammasome in acute MSU crystal-induced inflammation
doi.org/10.1002/art....
#medsky #rheumsky #immunosky
✨April Issue✨| Hyperuricaemia and gout in the Pacific
In this article, the authors provide an overview of gout and hyperuricaemia in Indigenous peoples of the Pacific region
#Rheumsky #Medsky
Free to read here: bit.ly/41LQgj2 🔓
Map of the Pacific region shown in the style of an image of polarised light micrograph images of uric acid crystals
✨Our April Issue is out now!✨ Featuring articles on:
- Hyperuricemia and gout in the Pacific🌏
- Targeting synovial joint stem and progenitor cells🎯
- The role of the immune system in OA 🧫
- Delineating inflammatory from non-inflammatory PsA🦴
#Rheumsky #Medsky
bit.ly/3FSVhxC
Screenshot of the NRR EBG articles
📣Did you know that we now publish Evidence-Based Guidelines?📣
You can view all of the EBGs that have been published in NRR using the link below (free to access!) 🔓
bit.ly/3CA9r5B
